LINC00092 Enhances LPP Expression to Repress Thyroid Cancer
                    Development via Sponging miR-542-3p

Huan Wang

doi:10.1055/a-2180-6624

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2024; 56(02): 150-158
DOI: 10.1055/a-2180-6624

Original Article: Endocrine Research

LINC00092 Enhances LPP Expression to Repress Thyroid Cancer Development via Sponging miR-542-3p

Authors

Huan Wang

¹General Practice Section, Wuhan University of Science and Technology Hospital, Wuhan, China

Abstract

LINC00092 is poorly expressed in Thyroid cancer (TC), while its role in TC tumorigenesis is still elusive. This study aimed to reveal the role and regulatory mechanism of LINC00092 in TC.

RNA immunoprecipitation and dual luciferase reporter assays were employed to ascertain the relationships among lipoma preferred partner (LPP), miR-542-3p, and LINC00092. qRT-PCR analysis was performed to detect their expression levels in TC. LPP protein productions were evaluated via western blotting. CCK-8, transwell, and colony formation assays were done to estimate TC cells’ biological functions. A murine xenograft model was built to observe tumor formation in vivo.

LINC00092 overexpression decreased the expression levels of miR-542-3p, and LPP was targeted by miR-542-3p. In TC cells and tissues, the elevation of miR-542-3p, and low amounts of LINC00092 and LPP can be observed. Both LINC00092 and SPAG6 were considered as the antineoplastic factors in TC since their overexpression dramatically repressed TC cells’ invasive and proliferative potentials, while miR-542-3p exerted the opposite functions in TC. The ectopic expression of LINC00092 also suppressed tumor growth in vivo. In addition, it revealed that miR-542-3p upregulation reversed LINC00092 overexpression-mediated effects on TC cells. At the same time, the enhanced influences of TC cells caused by miR-542-3p upregulation could be attenuated by the enforced LPP.

This study innovatively reveals that LINC00092 acts as an antineoplastic lncRNA to restrain the development of TC via regulating miR-542-3p/LPP. The findings of this study may provide a prospective drug target on LINC00092/miR-542-3p/LPP axis for the treatment of TC.

Key words

thyroid cancer - lncRNA - LINC00092 - miR-542-3p - LPP

Full Text

References

References
1 Huang Y, Prasad M, Lemon WJ. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001; 98: 15044-15049
2 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010; 22: 395-404
3 Mahmoudian-Sani MR, Jalali A, Jamshidi M. et al. Long non-coding RNAs in thyroid cancer: implications for pathogenesis, diagnosis, and therapy. Oncol Res Treat 2019; 42: 136-142
4 Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016; 375: 2307
5 Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 2016; 23: 313-322
6 Kreissl MC, Janssen MJR, Nagarajah J. Current treatment strategies in metastasized differentiated thyroid cancer. J Nucl Med 2019; 60: 9-15
7 Filetti S, Durante C, Hartl D. et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1856-1883
8 Lu W, Xu Y, Xu J. et al. Identification of differential expressed lncRNAs in human thyroid cancer by a genome-wide analyses. Cancer Med 2018; 7: 3935-3944
9 Zhao H, De Souza C, Kumar VE. et al. Long non-coding RNA signatures as predictors of prognosis in thyroid cancer: a narrative review. Ann Transl Med 2021; 9: 359
10 Ghafouri-Fard S, Mohammad-Rahimi H, Taheri M. The role of long non-coding RNAs in the pathogenesis of thyroid cancer. Exp Mol Pathol 2020; 112: 104332
11 Liu L, Yang J, Zhu X. et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J 2016; 283: 2326-2339
12 Fu XD, Liu CY, Liu YL. et al. LINC00261 regulates EBF1 to suppress malignant progression of thyroid cancer. Eur Rev Med Pharmacol Sci 2021; 25: 7626-7634
13 Jia M, Li Z, Pan M. et al. LINC-PINT suppresses the aggressiveness of thyroid cancer by downregulating miR-767-5p to induce TET2 expression. Mol Ther Nucleic Acids 2020; 22: 319-328
14 Zhao L, Ji G, Le X. et al. Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Cancer Res 2017; 77: 1369-1382
15 Wang X, Wang X, Huang G. et al. Lower expression of LINC00092 in lung adenocarcinoma might mean poorer prognosis: A study based on data mining and bioinformatics. Medicine (Baltimore) 2020; 99: e23012
16 Zhang Y, Jin T, Shen H. et al. Identification of long non-coding RNA expression profiles and co-expression genes in thyroid carcinoma based on the cancer genome atlas (TCGA) database. Med Sci Monit 2019; 25: 9752-9769
17 Chen Y, Gao H, Li Y. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-·1/Smads signaling pathway. Mol Cell Endocrinol 2020; 500: 110634
18 Zhang X, Zhang X, Jia Q. et al. LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis. BMC Cancer 2022; 22: 344
19 Althoff K, Lindner S, Odersky A. et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer 2015; 136: 1308-1320
20 Liu B, Li J, Zheng M. et al. MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2. Life Sci 2017; 188: 87-95
21 Zhang T, Liu W, Meng W. et al. Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-β/Smad signaling in hepatocellular carcinoma. Onco Targets Ther 2018; 11: 1929-1939
22 Yuan L, Yuan P, Yuan H. et al. miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1. Am J Cancer Res 2017; 7: 159-172
23 Wu HX, Wang GM, Lu X. et al. miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells. Eur Rev Med Pharmacol Sci 2017; 21: 108-114
24 Li J, Shao W, Feng H. MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. Biomed Pharmacother 2019; 110: 850-856
25 Peng G, Guan J, Leng P. et al. Circular RNA circ_0000515 adsorbs miR-542-3p to accelerate bladder cancer progression via up-regulating ILK expression. Aging (Albany NY) 2022; 14: 430-442
26 Petit MM, Mols R, Schoenmakers EF. et al. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 1996; 36: 118-129
27 Grunewald TG, Pasedag SM, Butt E. Cell Adhesion and transcriptional activity - defining the role of the novel protooncogene LPP. Transl Oncol 2009; 2: 107-116
28 Yang Y, Wang D, Tao K. et al. Circular RNA circLRCH3 inhibits proliferation, migration, and invasion of colorectal cancer cells through miRNA-223/LPP axis. Onco Targets Ther 2022; 15: 541-554
29 Kuriyama S, Yoshida M, Yano S. et al. LPP inhibits collective cell migration during lung cancer dissemination. Oncogene 2016; 35: 952-964
30 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29
31 Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017; 235: R43-R61
32 Erol V, Makay Ö, İçöz G. et al. The importance of staging systems for the determination of prognosis of well-differentiated thyroid cancer. Ulus Cerrahi Derg 2013; 29: 7-10
33 Guo K, Qian K, Shi Y. et al. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis 2021; 12: 1097
34 Liu H, Deng H, Zhao Y. et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res 2018; 37: 279
35 Yuan J, Song Y, Pan W. et al. LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene 2020; 39: 6664-6676
36 Zhao CM, Li LL, Xu JW. et al. LINC00092 suppresses the malignant progression of breast invasive ductal carcinoma through modulating SFRP1 expression by sponging miR-1827. Cell Transplant 2022; 31: 9636897221086967
37 Si C, Yu Q, Yao Y. Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. Exp Ther Med 2018; 15: 4515-4521
38 Liu X, Liu B, Li R. et al. miR-146a-5p Plays an oncogenic role in NSCLC via suppression of TRAF6. Front Cell Dev Biol 2020; 8: 847
39 Chen C, Zhang Z, Li J. et al. SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6. Onco Targets Ther 2018; 11: 6081-6090
40 Liu Q, Zhang W, Luo L. et al. Long noncoding RNA TUG1 regulates the progression of colorectal cancer through miR-542-3p/TRIB2 axis and Wnt/·-catenin pathway. Diagn Pathol 2021; 16: 47
41 Li Q, Liu W, Li S. et al. Long non-coding RNA CASC15 favors tumorigenesis and development of ovarian cancer via sponging miR-542-3p. Panminerva Med 2021; 63: 245-246